Cargando…

A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study

BACKGROUND: Stigma is a barrier to the uptake of buprenorphine to treat opioid use disorder. Harm reduction treatment models intend to minimize this stigma by organizing care around non-judgmental interactions with people who use drugs. There are few examples of implementing buprenorphine treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapadia, Shashi N., Griffin, Judith L., Waldman, Justine, Ziebarth, Nicolas R., Schackman, Bruce R., Behrends, Czarina N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815286/
https://www.ncbi.nlm.nih.gov/pubmed/33469774
http://dx.doi.org/10.1007/s11606-020-06409-6
_version_ 1783638197820981248
author Kapadia, Shashi N.
Griffin, Judith L.
Waldman, Justine
Ziebarth, Nicolas R.
Schackman, Bruce R.
Behrends, Czarina N.
author_facet Kapadia, Shashi N.
Griffin, Judith L.
Waldman, Justine
Ziebarth, Nicolas R.
Schackman, Bruce R.
Behrends, Czarina N.
author_sort Kapadia, Shashi N.
collection PubMed
description BACKGROUND: Stigma is a barrier to the uptake of buprenorphine to treat opioid use disorder. Harm reduction treatment models intend to minimize this stigma by organizing care around non-judgmental interactions with people who use drugs. There are few examples of implementing buprenorphine treatment using a harm reduction approach in a primary care setting in the USA. METHODS: We conducted a qualitative study by interviewing leadership, staff, and external stakeholders at Respectful, Equitable Access to Compassionate Healthcare (REACH) Medical in Ithaca, NY. REACH is a freestanding medical practice that provides buprenorphine treatment for opioid use disorder since 2018. We conducted semi-structured interviews with 17 participants with the objective of describing REACH’s model of care. We selected participants based on their position at REACH or in the community. Interviews were recorded, transcribed, and analyzed for themes using content analysis, guided by the CDC Evaluation Framework. RESULTS: REACH provided buprenorphine, primary care, and mental health services in a low-threshold model. We identified three themes related to delivery of buprenorphine treatment. First, an organizational mission to provide equitable and low-stigma healthcare, which was a key to organizational identity. Second, a low-threshold buprenorphine treatment approach that was critical, but caused concern about over-prescribing and presented logistical challenges. Third, creation and retention of a harm reduction-oriented workforce by offering value-based work and by removing administrative barriers providers may face elsewhere to providing buprenorphine treatment. CONCLUSIONS: A harm reduction primary care model can help reduce stigma for people who use drugs and engage in buprenorphine treatment. Further research is needed to evaluate whether this model leads to improved patient outcomes, can overcome community stakeholder concerns, and is sustainable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-020-06409-6.
format Online
Article
Text
id pubmed-7815286
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-78152862021-01-21 A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study Kapadia, Shashi N. Griffin, Judith L. Waldman, Justine Ziebarth, Nicolas R. Schackman, Bruce R. Behrends, Czarina N. J Gen Intern Med Original Research BACKGROUND: Stigma is a barrier to the uptake of buprenorphine to treat opioid use disorder. Harm reduction treatment models intend to minimize this stigma by organizing care around non-judgmental interactions with people who use drugs. There are few examples of implementing buprenorphine treatment using a harm reduction approach in a primary care setting in the USA. METHODS: We conducted a qualitative study by interviewing leadership, staff, and external stakeholders at Respectful, Equitable Access to Compassionate Healthcare (REACH) Medical in Ithaca, NY. REACH is a freestanding medical practice that provides buprenorphine treatment for opioid use disorder since 2018. We conducted semi-structured interviews with 17 participants with the objective of describing REACH’s model of care. We selected participants based on their position at REACH or in the community. Interviews were recorded, transcribed, and analyzed for themes using content analysis, guided by the CDC Evaluation Framework. RESULTS: REACH provided buprenorphine, primary care, and mental health services in a low-threshold model. We identified three themes related to delivery of buprenorphine treatment. First, an organizational mission to provide equitable and low-stigma healthcare, which was a key to organizational identity. Second, a low-threshold buprenorphine treatment approach that was critical, but caused concern about over-prescribing and presented logistical challenges. Third, creation and retention of a harm reduction-oriented workforce by offering value-based work and by removing administrative barriers providers may face elsewhere to providing buprenorphine treatment. CONCLUSIONS: A harm reduction primary care model can help reduce stigma for people who use drugs and engage in buprenorphine treatment. Further research is needed to evaluate whether this model leads to improved patient outcomes, can overcome community stakeholder concerns, and is sustainable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-020-06409-6. Springer International Publishing 2021-01-19 2021-07 /pmc/articles/PMC7815286/ /pubmed/33469774 http://dx.doi.org/10.1007/s11606-020-06409-6 Text en © Society of General Internal Medicine 2021
spellingShingle Original Research
Kapadia, Shashi N.
Griffin, Judith L.
Waldman, Justine
Ziebarth, Nicolas R.
Schackman, Bruce R.
Behrends, Czarina N.
A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study
title A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study
title_full A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study
title_fullStr A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study
title_full_unstemmed A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study
title_short A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study
title_sort harm reduction approach to treating opioid use disorder in an independent primary care practice: a qualitative study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815286/
https://www.ncbi.nlm.nih.gov/pubmed/33469774
http://dx.doi.org/10.1007/s11606-020-06409-6
work_keys_str_mv AT kapadiashashin aharmreductionapproachtotreatingopioidusedisorderinanindependentprimarycarepracticeaqualitativestudy
AT griffinjudithl aharmreductionapproachtotreatingopioidusedisorderinanindependentprimarycarepracticeaqualitativestudy
AT waldmanjustine aharmreductionapproachtotreatingopioidusedisorderinanindependentprimarycarepracticeaqualitativestudy
AT ziebarthnicolasr aharmreductionapproachtotreatingopioidusedisorderinanindependentprimarycarepracticeaqualitativestudy
AT schackmanbrucer aharmreductionapproachtotreatingopioidusedisorderinanindependentprimarycarepracticeaqualitativestudy
AT behrendsczarinan aharmreductionapproachtotreatingopioidusedisorderinanindependentprimarycarepracticeaqualitativestudy
AT kapadiashashin harmreductionapproachtotreatingopioidusedisorderinanindependentprimarycarepracticeaqualitativestudy
AT griffinjudithl harmreductionapproachtotreatingopioidusedisorderinanindependentprimarycarepracticeaqualitativestudy
AT waldmanjustine harmreductionapproachtotreatingopioidusedisorderinanindependentprimarycarepracticeaqualitativestudy
AT ziebarthnicolasr harmreductionapproachtotreatingopioidusedisorderinanindependentprimarycarepracticeaqualitativestudy
AT schackmanbrucer harmreductionapproachtotreatingopioidusedisorderinanindependentprimarycarepracticeaqualitativestudy
AT behrendsczarinan harmreductionapproachtotreatingopioidusedisorderinanindependentprimarycarepracticeaqualitativestudy